# An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors

> **NCT07639840** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Immune-related Dermatitis

## Interventions

- **DRUG:** Roflumilast 0.3% topical foam

## Key facts

- **NCT ID:** NCT07639840
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639840, "An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07639840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*